Cellebrite DI (NasdaqGS:CLBT) has put AI at the center of its story this month, rolling out Guardian Investigate worldwide alongside early access to Genesis, two tools aimed at digitizing and coordinating complex investigations.
See our latest analysis for Cellebrite DI.
The AI launches have come during a choppy period for the stock, with a 30 day share price return of 8.43% set against a 90 day share price decline of 25.83% and a three year total shareholder return of about 1.4x.
If these AI tools have your attention, it may be a useful moment to see what else is emerging in the sector by checking out 33 AI small caps
With Cellebrite DI sharing new AI products, a 1-year total return of about a 26% decline, and a three-year total return of roughly 1.4x, the key question is simple: is there value left here, or is the market already pricing in future growth?
Most Popular Narrative: 34.1% Undervalued
With a fair value estimate of $21.67 against a last close of $14.27, the most followed narrative sees considerable upside baked into Cellebrite DI's long run earnings power, built around subscription growth and margin potential.
The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.
Want to understand why this narrative supports a higher fair value? It leans heavily on recurring revenue, rising profitability, and a rich earnings multiple tied to future growth expectations.
Result: Fair Value of $21.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside view can weaken if US federal contract delays persist or if tighter privacy rules restrict how quickly Cellebrite can expand its digital forensics footprint.
Find out about the key risks to this Cellebrite DI narrative.
Next Steps
With sentiment clearly split between upside potential and real execution risks, it makes sense to move quickly and test the numbers yourself. To see exactly what investors are optimistic about, start by reviewing the 4 key rewards.
Looking for more investment ideas?
Do not stop with a single stock when there is a full market of ideas to compare, pressure test, and potentially improve your overall portfolio decisions.
- Target dependable cash generators by scanning 53 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
- Prioritise resilience by reviewing 68 resilient stocks with low risk scores so you can focus on businesses that score well on stability and balance sheet strength.
- Spot tomorrow's potential standouts early by checking the screener containing 26 high quality undiscovered gems before they draw broader market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com